Congress Is Investigating McKinsey Over Its Role in the Opioid Crisis

In a new assault on the global consulting giant McKinsey & Company, Congress on Friday started an investigation into the firm’s role in the opioid crisis, sending a letter demanding records related to its “business practices, conflicts of interest and management standards.”

The 12-page letter, which was sent by the House Committee on Oversight and Reform, asked for names of McKinsey clients in the health care industry as well as documents connected to its work with opioid manufacturers, distributors and retailers. The committee is also looking at how McKinsey’s consulting for drugmakers may conflict with work it has done for the Food and Drug Administration.

By advising opioid makers and “the federal agency regulating their conduct,” McKinsey “may have had a significant negative impact on Americans’ health,” the committee said.

The letter was signed by the committee’s chairwoman, Representative Carolyn B. Maloney of New York, who requested that McKinsey produce the documents by Nov. 19. McKinsey has a policy of not identifying its clients or the advice it gives.

Continue:
[link to onlynews.today (secure)]

In 1996, HIPAA was enacted.
In 1996, Oxycodone was released on the masses.
Nothing to see here.